114 related articles for article (PubMed ID: 8283086)
1. [Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
Takano H; Miyamoto Y; Kaneko M; Matsuwaka R; Kuratani T; Amemiya A; Nakano S; Matsuda H
Nihon Kyobu Geka Gakkai Zasshi; 1993 Nov; 41(11):2166-73. PubMed ID: 8283086
[TBL] [Abstract][Full Text] [Related]
2. Nafamostat mesilate reduces blood loss during open heart surgery.
Murase M; Usui A; Tomita Y; Maeda M; Koyama T; Abe T
Circulation; 1993 Nov; 88(5 Pt 2):II432-6. PubMed ID: 8222190
[TBL] [Abstract][Full Text] [Related]
3. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery.
Tanaka K; Kondo C; Takagi K; Sato T; Yada I; Yuasa H; Kusagawa M
ASAIO J; 1993; 39(3):M545-9. PubMed ID: 8268595
[TBL] [Abstract][Full Text] [Related]
4. Nafamostat mesilate administration during cardiopulmonary bypass decreases postoperative bleeding after cardiac surgery.
Sato T; Tanaka K; Kondo C; Morimoto T; Yada I; Yuasa H; Kusagawa M; Deguchi K
ASAIO Trans; 1991; 37(3):M194-5. PubMed ID: 1751106
[TBL] [Abstract][Full Text] [Related]
5. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
[TBL] [Abstract][Full Text] [Related]
6. Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials.
Usui A; Hiroura M; Kawamura M; Hibi M; Yoshida K; Murakami F; Tomita Y; Ooshima H; Murase M
Ann Thorac Surg; 1996 Nov; 62(5):1404-11. PubMed ID: 8893576
[TBL] [Abstract][Full Text] [Related]
7. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery.
Chomiak PN; Walenga JM; Koza MJ; Reilly TM; Turlapathy P; Pifarre R
Circulation; 1993 Nov; 88(5 Pt 2):II407-12. PubMed ID: 7993389
[TBL] [Abstract][Full Text] [Related]
8. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC
J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027
[TBL] [Abstract][Full Text] [Related]
9. Nafamostat mesilate reduces blood cell adhesion to cardiopulmonary bypass circuits: an in-vitro study.
Hiroura M; Usui A; Kawamura M; Hibi M; Iwase J
J Extra Corpor Technol; 1994 Sep; 26(3):121-5. PubMed ID: 10150679
[TBL] [Abstract][Full Text] [Related]
10. Heparin-coated versus uncoated extracorporeal circuit in patients undergoing coronary artery bypass graft surgery.
Oliver WC; Nuttall GA; Ereth MH; Santrach PJ; Buda DA; Schaff HV
J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):165-70. PubMed ID: 12698396
[TBL] [Abstract][Full Text] [Related]
11. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
[TBL] [Abstract][Full Text] [Related]
12. Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits.
Borowiec J; Bagge L; Saldeen T; Thelin S
Thorac Cardiovasc Surg; 1997 Aug; 45(4):163-7. PubMed ID: 9323816
[TBL] [Abstract][Full Text] [Related]
13. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental Extracorporeal Life Support (ECLS).
Mellgren K; Skogby M; Friberg LG; Tengborn L; Wadenvik H
Thromb Haemost; 1998 Feb; 79(2):342-7. PubMed ID: 9493588
[TBL] [Abstract][Full Text] [Related]
14. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
Bagge L; Borowiec JW; Thelin S; Hultman J
Scand Cardiovasc J; 1997; 31(6):275-81. PubMed ID: 9498931
[TBL] [Abstract][Full Text] [Related]
15. Clinical heparin coated cardiopulmonary bypass: reduction of systemic heparin requirements for redo cardiac surgery.
Ladowski JS; Schatzlein MH; Peterson AC; Deschner WP; Matheis R; Ellenwood M; Bach J; Moldovan L; McKamey D
ASAIO J; 1996; 42(1):34-6. PubMed ID: 8808455
[TBL] [Abstract][Full Text] [Related]
16. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
Bagge L; Borowiec JW; Thelin S; Hultman J
Scand Cardiovasc J; 1997; 31(5):275-81. PubMed ID: 9406294
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of a silicone coated hollow fiber oxygenator.
Shimono T; Shomura Y; Tani K; Shimamoto A; Hioki I; Tokui T; Onoda K; Takao M; Shimpo H; Yada I
ASAIO J; 1997; 43(5):M735-9. PubMed ID: 9360143
[TBL] [Abstract][Full Text] [Related]
18. A comparative evaluation of the effect of pump type and heparin-coated surfaces on platelets during cardiopulmonary bypass.
Misoph M; Babin-Ebell J; Schwender S
Thorac Cardiovasc Surg; 1997 Dec; 45(6):302-6. PubMed ID: 9477463
[TBL] [Abstract][Full Text] [Related]
19. Effect of polymer coating (poly 2-methoxyethylacrylate) of the oxygenator on hemostatic markers during cardiopulmonary bypass in children.
Eisses MJ; Geiduschek JM; Jonmarker C; Cohen GA; Chandler WL
J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):28-34. PubMed ID: 17289476
[TBL] [Abstract][Full Text] [Related]
20. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
